Gene: DNAI7
Official Full Name: dynein axonemal intermediate chain 7provided by HGNC
Gene Summary: Predicted to enable beta-tubulin binding activity and microtubule binding activity. Predicted to be located in cilium and microtubule cytoskeleton. Predicted to be part of axonemal dynein complex. Predicted to be active in axoneme and cytoplasmic microtubule. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO18226 | DNAI7 Knockout cell line (HeLa) | Human | DNAI7 | 1:3~1:6 | Negative | Online Inquiry |
KO18227 | DNAI7 Knockout cell line (HCT 116) | Human | DNAI7 | 1:2~1:4 | Negative | Online Inquiry |
KO18228 | DNAI7 Knockout cell line (HEK293) | Human | DNAI7 | 1:3~1:6 | Negative | Online Inquiry |
KO18229 | DNAI7 Knockout cell line (A549) | Human | DNAI7 | 1:3~1:4 | Negative | Online Inquiry |
DNAI7 Gene Knockout Cell Lines are a valuable research tool specifically designed to facilitate the study of the DNAI7 gene, which is implicated in various respiratory disorders due to its role in the motility of cilia. These genetically modified cell lines have been engineered to have a complete deletion of the DNAI7 gene, allowing researchers to observe the resultant phenotypic and functional changes that occur in cilia structure and motility. The knockout mechanism typically employs CRISPR/Cas9 technology, resulting in precise gene editing that significantly improves experimental reliability.
The key functions of the DNAI7 Gene Knockout Cell Lines lie in their ability to serve as model systems for investigating the molecular pathways associated with cilia dysfunction, including their formation and movement. This is particularly significant in understanding diseases such as primary ciliary dyskinesia (PCD), where impaired cilia function leads to chronic respiratory issues and infertility. Researchers can utilize these cell lines to test therapeutic approaches, screen potential drugs, and elucidate the mechanisms at play in ciliary assembly and function, ultimately promoting advancements in gene therapy and regenerative medicine.
What sets the DNAI7 Gene Knockout Cell Lines apart from competitor products is their rigorous validation and characterization, ensuring that the knockout phenotype faithfully represents the functional loss of DNAI7. Furthermore, these cell lines are compatible with standard cell culture methods and readily integrable into existing workflows, minimizing the barrier to adoption. Researchers can accelerate their studies without the need for extensive adjustments to their laboratory setups.
The value of this product extends beyond academic research; it holds significant promise for translational medicine. By providing a platform for investigating disease mechanisms and testing novel treatments, these knockout cell lines enable clinicians and pharmaceutical researchers to bridge the gap between bench and bedside.
With a reputation for delivering high-quality biological products, our company brings expertise across genetic engineering and cell biology, ensuring that you have reliable tools to advance your research and clinical applications effectively. Our commitment to innovation and support positions us as a trusted partner in your scientific endeavors.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.